🇪🇺 Doribax in European Union

EMA authorised Doribax on 25 July 2008

Marketing authorisation

EMA — authorised 25 July 2008

  • Application: EMEA/H/C/000891
  • Marketing authorisation holder: Janssen-Cilag International NV
  • Local brand name: Doribax
  • Indication: Doribax is indicated for the treatment of the following infections in adults: nosocomial pneumonia (including ventilator-associated pneumonia); complicated intra-abdominal infections; complicated urinary tract infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
  • Status: withdrawn

Read official source →

Doribax in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in European Union

Frequently asked questions

Is Doribax approved in European Union?

Yes. EMA authorised it on 25 July 2008.

Who is the marketing authorisation holder for Doribax in European Union?

Janssen-Cilag International NV holds the EU marketing authorisation.